40 related articles for article (PubMed ID: 38594735)
21. Crizotinib in ALK
Theilen TM; Soerensen J; Bochennek K; Becker M; Schwabe D; Rolle U; Klingebiel T; Lehrnbecher T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286567
[TBL] [Abstract][Full Text] [Related]
22. Update of Diagnosis and Targeted Therapy for ALK
Wang QA; Chen HW; Wu RC; Wu CE
Curr Treat Options Oncol; 2023 Dec; 24(12):1683-1702. PubMed ID: 37938503
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
24. A Novel ALK-THBS1 Fusion in a Laryngeal Inflammatory Myofibroblastic Tumour: A Case Report and Literature Review.
Elktaibi A; Benzerdjeb N; Ameur F; Daveau C; Tantot J; Costes Martineau V
Head Neck Pathol; 2020 Jun; 14(2):454-458. PubMed ID: 31368077
[TBL] [Abstract][Full Text] [Related]
25. Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer.
Wang W; Sun X; Hui Z
Oncol Res Treat; 2019; 42(11):599-606. PubMed ID: 31527380
[TBL] [Abstract][Full Text] [Related]
26. Intraarticular Inflammatory Myofibroblastic Tumor of the Left Knee With ALK-CARS Fusion Detected With Archer Fusionplex Sarcoma NGS Panel: Case Report and Literature Review.
Pineda-Díaz J; Solar I; Hershkovitz D; Drukman I; Sher O
Int J Surg Pathol; 2021 Apr; 29(2):216-222. PubMed ID: 32631118
[TBL] [Abstract][Full Text] [Related]
27. ALK-immunoreactive neoplasms.
Minoo P; Wang HY
Int J Clin Exp Pathol; 2012; 5(5):397-410. PubMed ID: 22808292
[TBL] [Abstract][Full Text] [Related]
28. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
[TBL] [Abstract][Full Text] [Related]
29. Role and targeting of anaplastic lymphoma kinase in cancer.
Della Corte CM; Viscardi G; Di Liello R; Fasano M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
Mol Cancer; 2018 Feb; 17(1):30. PubMed ID: 29455642
[TBL] [Abstract][Full Text] [Related]
30. Spontaneous regression of ALK fusion protein-positive non-small cell lung carcinoma: a case report and review of the literature.
Walls M; Walls GM; James JA; Crawford KT; Abdulkhalek H; Lynch TB; Peace AJ; McManus TE; Evans OR
BMC Pulm Med; 2020 Aug; 20(1):209. PubMed ID: 32762670
[TBL] [Abstract][Full Text] [Related]
31. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
Lee JC; Li CF; Huang HY; Zhu MJ; Mariño-Enríquez A; Lee CT; Ou WB; Hornick JL; Fletcher JA
J Pathol; 2017 Feb; 241(3):316-323. PubMed ID: 27874193
[TBL] [Abstract][Full Text] [Related]
32. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review.
Lingling X; Maoxi C; Wei Y; Jieting Z; Yuanyuan Y; Ning X
Lung Cancer; 2023 Dec; 186():107415. PubMed ID: 37907052
[TBL] [Abstract][Full Text] [Related]
33. A Rare Case of Inflammatory Myofibroblastic Tumor of the Prostate and Review of the Literature.
Kim MS; Lim SC
In Vivo; 2020; 34(4):2043-2048. PubMed ID: 32606180
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous inflammatory myofibroblastic tumor with CARS-ALK fusion: Case report and literature review.
McCollum KJ; Jour G; Al-Rohil RN
J Cutan Pathol; 2022 Sep; 49(9):795-801. PubMed ID: 35560368
[TBL] [Abstract][Full Text] [Related]
35. DCTN1-ALK gene fusion in inflammatory myofibroblastic tumor (IMT) of the CNS.
Vidrine DW; Berry JF; Garbuzov A; Falcon C; Tubbs RS; Bui CJ
Childs Nerv Syst; 2021 Jul; 37(7):2147-2151. PubMed ID: 34014367
[TBL] [Abstract][Full Text] [Related]
36. Anaplastic lymphoma kinase-positive pulmonary inflammatory myofibroblastic tumour: a case report.
Tong D; Chisholm J; Madden B; Ahmed M
J Med Case Rep; 2024 Apr; 18(1):167. PubMed ID: 38594735
[TBL] [Abstract][Full Text] [Related]
37. How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O; Kuzhan O; Koca S; Telli TA; Basoglu T; Ercelep O; Filinte D; Sengul Y; Arikan H; Kaya S; Babacan NA; Dane F; Yumuk PF
J Oncol Pharm Pract; 2020 Jun; 26(4):1011-1018. PubMed ID: 31615346
[TBL] [Abstract][Full Text] [Related]
38. Anaplastic lymphoma kinase inhibitor therapy in the treatment of inflammatory myofibroblastic tumors in pediatric patients: Case reports and literature review.
Craig E; Wiltsie LM; Beaupin LK; Baig A; Kozielski R; Rothstein DH; Li V; Twist CJ; Barth M
J Pediatr Surg; 2021 Dec; 56(12):2364-2371. PubMed ID: 33676744
[TBL] [Abstract][Full Text] [Related]
39. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
40. Sustained complete response on crizotinib in primary lung inflammatory myofibroblastic tumor - Case report and literature review.
Mittal A; Gupta A; Dhamija E; Barwad A; Rastogi S
Monaldi Arch Chest Dis; 2021 Mar; 91(3):. PubMed ID: 33794589
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
